Call for patient input on nirmatrelvir/ritonavir (Paxlovid®) for mild-to-moderate COVID-19 « JointHealth™ express

JointHealth™ express September 20, 2023

Call for patient input on nirmatrelvir/ritonavir (Paxlovid®) for mild-to-moderate COVID-19

The Canadian Agency for Drugs and Technologies in Health (CADTH) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for Paxlovid for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization and death.

Clinical trials have shown nirmatrelvir/ritonavir (Paxlovid®) treatment can reduce severity of COVID-19 symptoms and reduce hospitalization and death. However, therapy must be started within 5 days of symptoms.

According to the Canadian Rheumatology Association, immunocompromised people living with an inflammatory arthritis such as rheumatoid arthritis are at higher risk of serious illness from COVID-19. Paxlovid treatment has proven to help prevent symptoms from getting worse and lowering the chance that patients with inflammatory arthritis need to go to hospital for COVID-19.

Please send us your input by Sunday, September 24, 2023. Your input will be anonymous. Contact us at feedback@jointhealth.org to provide your input or arrange for a phone interview at 604-974-1366.